CSL News: CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) - 4th Jan 2024, 12:00am

annb0t

Top 20
-    Hizentra® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S.
-    Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the U.S.

KING OF PRUSSIA, Pa., Jan. 3, 2024 /PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcu...

>>> Read more: CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
 
Top Bottom